← Eichor
Study identifier: NCT02662751 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA

Condition: Stroke · Ischemic Attack, Transient  ·  Sponsor: Centre Hospitalier Universitaire de Nīmes

PhaseNA
Planned participants260
Who can joinAll sexes, 18 Years to 89 Years
Healthy volunteersNo

About this study

The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. The first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/TIA imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.

This description comes directly from the study's public registry record.

Talk to the study team

Francesco Macri, MD  ·  +33.(0)6.19.42.18.52  ·  francesco.macri@chu-nimes.fr

Carey Suehs, PhD  ·  +33.(0)4.66.68.67.88  ·  carey.suehs@chu-nimes.fr

Always discuss trial participation with your own doctor first.

Locations (2)

CHRU de Montpellier - Hôpital Gui de ChauliacMontpellier, FranceRecruiting
CHRU de Nîmes - Hôpital Universitaire CarémeauNîmes, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02662751